Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.
A new report reveals more than 180 companies are actively developing over 200 PD-1 and PD-L1 inhibitors, a class of immunotherapies that boost the immune system to fight cancer. These drugs target various cancers including lung, bladder, liver, and e...
